Merck & Co. Inc. (MRK) and Moderna, Inc. (MRNA) have initiated a pivotal Phase 3 trial for their investigational neoantigen therapy, V940 (mRNA-4157), in combination with Keytruda (pembrolizumab) for non-small cell lung cancer (NSCLC) patients. This trial, known as INTerpath-009, focuses on patients who did not achieve a complete response after receiving neoadjuvant Keytruda plus chemotherapy. The first patients have started enrolling in Canada, and global recruitment is ongoing. This development follows a series of other trials evaluating V940 in combination with Keytruda for different types of cancers.